Unsurprisingly, procedures aimed at mitigating CD4+ T cell activation, e.g. with checkpoint inhibitors or antigen-mediated tolerization, are effective in EAE models, but have not been approved for treatment of MS. Here, CD4 is linked to myeloid sarcoma.